Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 81 articles:
HTML format



Single Articles


    August 2022
  1. GARDNER AR, Ma Y, Bacchetti P, Price JC, et al
    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
    J Infect Dis. 2022 Aug 11. pii: 6650396. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  2. PEREZ-GARCIA F, Vazquez-Moron S, Burgueno-Garcia I, Jose Munoz-Gomez M, et al
    Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study.
    J Infect Dis. 2022 Jun 27. pii: 6618639. doi: 10.1093.
    PubMed     Abstract available


    May 2022
  3. OSTER G, Bornheimer R, Ottino K
    Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
    PubMed    


  4. BRAKENHOFF SM, de Knegt RJ, Oliveira J, van der Eijk AA, et al
    Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients.
    J Infect Dis. 2022 May 23. pii: 6590452. doi: 10.1093.
    PubMed     Abstract available


  5. MOHAREB AM, Liu AF, Kim AY, Coffie PA, et al
    Clearance of hepatitis B "e" antigen in untreated chronic HBV infection: a systematic review and meta-analysis.
    J Infect Dis. 2022 May 2. pii: 6576758. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  6. MONTANARI NR, Conceicao-Neto N, Van Den Wyngaert I, Van Oord GW, et al
    Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients.
    J Infect Dis. 2022;225:1471-1476.
    PubMed     Abstract available


    March 2022
  7. RICO MONTANARI N, Ramirez R, Van Buuren N, van den Bosch TPP, et al
    Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen.
    J Infect Dis. 2022;225:1081-1090.
    PubMed     Abstract available


  8. HALL EW, Weng MK, Harris AM, Schillie S, et al
    Assessing the cost-utility of universal hepatitis B vaccination among adults.
    J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  9. CATLETT B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, et al
    Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.
    J Infect Dis. 2022 Feb 12. pii: 6527696. doi: 10.1093.
    PubMed     Abstract available


    January 2022
  10. SPRADLING PR, Xing J, Zhong Y, Rupp LB, et al
    Incidence of malignancies among patients with chronic hepatitis B in US health care organizations, 2006-2018.
    J Infect Dis. 2022 Jan 17. pii: 6510085. doi: 10.1093.
    PubMed     Abstract available


  11. KHALFI P, Suspene R, Caval V, Thiers V, et al
    APOBEC3C S188I polymorphism enhances context specific editing of Hepatitis B virus genome.
    J Infect Dis. 2022 Jan 12. pii: 6504007. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  12. LIU S, Deng R, Zhou B, Liang X, et al
    Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy.
    J Infect Dis. 2021 Dec 21. pii: 6472568. doi: 10.1093.
    PubMed     Abstract available


  13. CHIEN-HUNG C, Peng CY, Kuo YH, Hu TH, et al
    Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients.
    J Infect Dis. 2021 Dec 11. pii: 6459556. doi: 10.1093.
    PubMed     Abstract available


  14. COSTAFREDA MI, Sauleda S, Rico A, Piron M, et al
    Detection of non-enveloped hepatitis E virus in plasma of infected blood donors.
    J Infect Dis. 2021 Dec 4. pii: 6449510. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  15. STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  16. PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
    Hepatitis B Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  17. AZMAN AS, Paul KK, Bhuiyan TR, Koyuncu A, et al
    Hepatitis E in Bangladesh: Insights from a National Serosurvey.
    J Infect Dis. 2021 Sep 22. pii: 6373659. doi: 10.1093.
    PubMed     Abstract available


  18. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    PubMed     Abstract available


  19. RYDELL GE, Prakash K, Larsson SB, Skoglund C, et al
    Quantification of viral RNA in multiple pieces of explant liver tissue shows distinct focal differences of hepatitis B infection.
    J Infect Dis. 2021 Sep 17. pii: 6371942. doi: 10.1093.
    PubMed     Abstract available


    August 2021
  20. CHANG KC, Chang MH, Chen HL, Wu JF, et al
    Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 years: moving toward the Eradication of HBV.
    J Infect Dis. 2021 Aug 7. pii: 6345224. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  21. JOHNSON VALIENTE A, Liem KS, Schwarz KB, Rosenthal P, et al
    The Inflammatory Cytokine Profile Associated with Liver Damage is Broader and Stronger in Chronic Hepatitis B Patients Compared to Acute Hepatitis B Patients.
    J Infect Dis. 2021 Jul 21. pii: 6324833. doi: 10.1093.
    PubMed     Abstract available


  22. SPRADLING PR, Xing J, Harris AM, Ly KN, et al
    Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018.
    J Infect Dis. 2021 Jul 12. pii: 6319558. doi: 10.1093.
    PubMed     Abstract available


  23. GU S, Wang W, Ye G, Chen C, et al
    Hepatocyte-derived L-carnitine restricts hepatitis B surface antigen loss through an immunosuppressive effect on germinal center-related immune cells.
    J Infect Dis. 2021 Jul 2. pii: 6313212. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  24. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  25. HSU YC, Yeh ML, Wong GL, Chen CH, et al
    Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
    J Infect Dis. 2021 May 17. pii: 6276897. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  26. GONZALEZ HC, Trudeau S, Gordon SC
    Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies.
    J Infect Dis. 2021 Apr 27. pii: 6254533. doi: 10.1093.
    PubMed    


  27. LY KN, Xing J, Spradling PR
    Trends in Prevalence and Characteristics of Resolved and Current Hepatitis B among US-Born Persons: National Health and Nutrition Examination Survey, 2001-2018.
    J Infect Dis. 2021 Apr 27. pii: 6254685. doi: 10.1093.
    PubMed     Abstract available


  28. YUAN W, Huang D, Wu D, Chen Y, et al
    Peg IFN-a Treatment Enhanced the Inhibitory Effect of NK Cells on the Differentiation and Proliferation of CD4 +CD25 + Tregs via IFN-gamma in Chronic Hepatitis B.
    J Infect Dis. 2021 Apr 19. pii: 6236316. doi: 10.1093.
    PubMed     Abstract available


  29. LIU Z, Huang CJ, Huang YH, Pan MH, et al
    HLA zygosity increases risk of hepatitis B virus-associated hepatocellular carcinoma.
    J Infect Dis. 2021 Apr 14. pii: 6225842. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  30. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  31. WU W, Wu D, Yan W, Wang Y, et al
    Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p.
    J Infect Dis. 2021;223:686-698.
    PubMed     Abstract available


  32. CHUAYPEN N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis. 2021 Feb 17. pii: 6141513. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  33. KHERA T, Du Y, Todt D, Deterding K, et al
    Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.
    J Infect Dis. 2021 Jan 31. pii: 6124746. doi: 10.1093.
    PubMed     Abstract available


    December 2020
  34. KIRKEGAARD-KLITBO DM, Bendtsen F, Lundgren J, de Knegt RJ, et al
    Increased prevalence of liver fibrosis in people living with HIV without viral hepatitis compared to population controls.
    J Infect Dis. 2020 Dec 15. pii: 6035145. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  35. LI J, Yang HI, Yeh ML, Le MH, et al
    Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B.
    J Infect Dis. 2020 Nov 29. pii: 6010568. doi: 10.1093.
    PubMed     Abstract available


  36. JEYARAJAN AJ, Chung RT
    Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  37. BAJIS S, Applegate TL, Grebely J, Matthews GV, et al
    Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  38. CHAPPELL CA, Jonas MM
    Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
    J Infect Dis. 2020;222.
    PubMed    


  39. THOMAS DL
    30 Years on the Road to Hepatitis C Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  40. NAGGIE S, Wyles D
    Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  41. FALADE-NWULIA O, Sulkowski MS
    Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  42. TROOSKIN SB, Dore G, Kostman J
    We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  43. ROCKSTROH JK, Boesecke C
    Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  44. KAPPUS MR, Wolfe CR, Muir AJ
    Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  45. HALEY DF, Edmonds A, Ramirez C, French AL, et al
    Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV.
    J Infect Dis. 2020 Nov 3. pii: 5952700. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  46. VERGARA C, Valencia A, Thio CL, Goedert JJ, et al
    A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
    J Infect Dis. 2020 Oct 29. pii: 5943036. doi: 10.1093.
    PubMed     Abstract available


  47. LIN KY, Fang CT
    Public health responses to person-to-person hepatitis A outbreaks.
    J Infect Dis. 2020 Oct 24. pii: 5937234. doi: 10.1093.
    PubMed    


  48. HOFMEISTER MG, Xing J, Foster MA, Augustine RJ, et al
    Hepatitis A person-to-person outbreaks: Epidemiology, morbidity burden, and factors associated with hospitalization - Multiple States, 2016-2019.
    J Infect Dis. 2020 Oct 24. pii: 5937233. doi: 10.1093.
    PubMed     Abstract available


  49. YOSHIKAWA S, Yoshio S, Yoshida Y, Tsutsui Y, et al
    Impact of Immune Reconstitution-induced Hepatic Flare on HBsAg Loss in HBV/HIV-1-Coinfected Patients.
    J Infect Dis. 2020 Oct 19. pii: 5929874. doi: 10.1093.
    PubMed     Abstract available


  50. CHEN S, Zhang Z, Wang Y, Fang M, et al
    Quasispecies pattern of hepatitis B virus predicts hepatocellular carcinoma using deep-sequencing and machine learning.
    J Infect Dis. 2020 Oct 13. pii: 5922597. doi: 10.1093.
    PubMed     Abstract available


  51. MESALAM AA
    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    PubMed    


  52. DEZANET LNC, Maylin S, Gabassi A, Rougier H, et al
    Erratum to: Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
    J Infect Dis. 2020 Oct 7. pii: 5918836. doi: 10.1093.
    PubMed    


    September 2020
  53. RYDELL GE, Larsson SB, Prakash K, Andersson M, et al
    Abundance of non-circular intrahepatic hepatitis B virus DNA may reflect frequent integration into human DNA in chronically infected patients.
    J Infect Dis. 2020 Sep 10. pii: 5903701. doi: 10.1093.
    PubMed     Abstract available


  54. JORDAN AE, Cleland CM, Wyka K, Schackman BR, et al
    Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  55. LEE AB, Karumberia S, Gilmore A, Williams E, et al
    Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  56. ROWAN SE, Kamis KF, Beum R, Bryan K, et al
    Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  57. SHERBUK JE, Knick TK, Canan C, Ross P, et al
    Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  58. JORDAN AE, Cleland CM, Schackman BR, Wyka K, et al
    Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  59. ASSOUMOU SA, Paniagua SM, Linas BP, Wang J, et al
    Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  60. WESNER CA, Zhang W, Melstad S, Ruen E, et al
    Assessing County-Level Vulnerability for Opioid Overdose and Rapid Spread of Human Immunodeficiency Virus and Hepatitis C Infection in South Dakota.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  61. WINETSKY D, Burack D, Antoniou P, Garcia B, et al
    Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  62. SPRINGER SA, Barocas JA, Wurcel A, Nijhawan A, et al
    Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


    August 2020
  63. WU JF, Chang KC, Ni YH, Hsu HY, et al
    Impacts of the percentage of basal core promoter mutation on the progression of liver fibrosis after HBeAg-seroconversion.
    J Infect Dis. 2020 Aug 29. pii: 5899201. doi: 10.1093.
    PubMed     Abstract available


  64. CAPPY P, Lucas Q, Kankarafou N, Sureau C, et al
    No Evidence of HCV-Assisted HDV Propagation in a Large Cohort of Hepatitis C Positive Blood Donors.
    J Infect Dis. 2020 Aug 17. pii: 5893459. doi: 10.1093.
    PubMed     Abstract available


  65. WIJAYA RS, Read SA, Selvamani SP, Schibeci S, et al
    Hepatitis C virus eradication with interferon free, DAA-based therapy results in KLRG1+, hepatitis C virus-specific memory natural killer cells.
    J Infect Dis. 2020 Aug 10. pii: 5890638. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  66. CATLETT B, Bajis S, Starr M, Dore GJ, et al
    Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples.
    J Infect Dis. 2020 Jul 25. pii: 5876378. doi: 10.1093.
    PubMed     Abstract available


  67. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study.
    J Infect Dis. 2020 Jul 2. pii: 5866494. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  68. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals.
    J Infect Dis. 2020 Jun 25. pii: 5862583. doi: 10.1093.
    PubMed     Abstract available


  69. MEHROTRA A, D'Angelo JA, Romney-Vanterpool A, Chu T, et al
    IFN-alpha Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T-Cell Proliferation.
    J Infect Dis. 2020;222:148-157.
    PubMed     Abstract available


  70. LE AK, Yang HI, Yeh ML, Jin M, et al
    Development and validation of a risk score for liver cirrhosis prediction in untreated and treated chronic hepatitis B.
    J Infect Dis. 2020 Jun 11. pii: 5856138. doi: 10.1093.
    PubMed     Abstract available


  71. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication.
    J Infect Dis. 2020 Jun 9. pii: 5854965. doi: 10.1093.
    PubMed     Abstract available


  72. TAKEUCHI Y, Tsuge M, Tsushima K, Suehiro Y, et al
    Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
    J Infect Dis. 2020 Jun 9. pii: 5854912. doi: 10.1093.
    PubMed     Abstract available


  73. NAGGIE S, Lusk S, Thompson JW, Mock M, et al
    Metabolomic signature as a predictor of liver disease events in patients with HIV/HCV co-infection.
    J Infect Dis. 2020 Jun 5. pii: 5851922. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  74. RONG G, Chen Y, Yu Z, Li Q, et al
    Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients with Chronic Hepatitis B Treated with Entecavir: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
    J Infect Dis. 2020 May 21. pii: 5841650. doi: 10.1093.
    PubMed     Abstract available


  75. ANTHONY DD, Sulkowski MS, Smeaton LM, Damjanovska S, et al
    HCV DAA Therapy in Persons with HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation.
    J Infect Dis. 2020 May 15. pii: 5836999. doi: 10.1093.
    PubMed     Abstract available


  76. CHANG WY, Chiu YC, Chiu FW, Hsu YC, et al
    High Risk of clinical relapse in HBV-infected patients after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy.
    J Infect Dis. 2020 May 12. pii: 5836326. doi: 10.1093.
    PubMed     Abstract available


  77. DASGUPTA S, Imamura M, Gorstein E, Nakahara T, et al
    Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration.
    J Infect Dis. 2020 May 4. pii: 5828592. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  78. SONNEVELD MJ, Hansen BE, Brouwer WP, Chan HL, et al
    hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study.
    J Infect Dis. 2020 Apr 21. pii: 5823493. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  79. SAKAMOTO K, Umemura T, Ito K, Okumura A, et al
    Virological Factors Associated With the Occurrence of Hepatitis B Virus (HBV) Reactivation in Patients With Resolved HBV Infection Analyzed Through Ultradeep Sequencing.
    J Infect Dis. 2020;221:400-407.
    PubMed     Abstract available


    August 2019
  80. KOSLOSKI MP, Oberoi R, Wang S, Viani RM, et al
    Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.
    J Infect Dis. 2019 Aug 29. pii: 5556482. doi: 10.1093.
    PubMed     Abstract available


  81. SALPINI R, Pietrobattista A, Piermatteo L, Basso MS, et al
    Establishment of a seronegative occult infection with an active HBV reservoir enriched of vaccine escape mutations in a vaccinated infant after liver transplant.
    J Infect Dis. 2019 Aug 14. pii: 5550108. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: